Price
Target price
€29.20
€29.20
-1.020%
-0.3
-1.020%
€53.50
07.07.26 / Stuttgart Stock Exchange
WKN: A1XCY0 / Symbol: RARE / Name: Ultragenyx / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Ultragenyx Pharmaceutical Inc. Stock
A loss of -1.020% shows a downward development for Ultragenyx Pharmaceutical Inc..
The stock is an absolute favorite of our community with 27 Buy predictions and no Sell predictions.
As a result the target price of 53 € shows a very positive potential of 81.51% compared to the current price of 29.2 € for Ultragenyx Pharmaceutical Inc..
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
S********** s********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -1.020% | 1.280% | 55.279% | -12.365% | 74.226% | -27.550% | -60.446% |
| Ligand Pharmaceuticals | 0.000% | 1.449% | 35.922% | 184.264% | 68.675% | 324.242% | 157.117% |
| United Therapeutics | -0.870% | 4.136% | 3.481% | 99.233% | 15.493% | 155.435% | 210.377% |
| Ionis Pharmaceuticals Inc. | -0.950% | 7.052% | 16.992% | 112.062% | 11.242% | 98.373% | 128.883% |
Comments
Ultragenyx Pharmaceutical (RARE) had its price target raised by Royal Bank Of Canada from $35.00 to $40.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target raised by Cantor Fitzgerald from $84.00 to $96.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target lowered by Guggenheim from $52.00 to $43.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
On May 14, 2026, Krensavage Asset Management disclosed it bought 241,245 shares of Ultragenyx Pharmaceutical (NASDAQ:RARE), an estimated $5.43 million trade based on quarterly average pricing.
